Novo Nordisk A/S

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, LLY has a market cap of 952.9B. Regarding current trading prices, NVO is priced at $48.45, while LLY trades at $1,023.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas LLY's P/E ratio is 43.99. In terms of profitability, NVO's ROE is +0.61%, compared to LLY's ROE of +0.98%. Regarding short-term risk, NVO is less volatile compared to LLY. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check LLY's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, AZN has a market cap of 633.8B. Regarding current trading prices, NVO is priced at $48.45, while AZN trades at $208.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas AZN's P/E ratio is 31.30. In terms of profitability, NVO's ROE is +0.61%, compared to AZN's ROE of +0.23%. Regarding short-term risk, NVO is less volatile compared to AZN. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check AZN's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, JNJ has a market cap of 584.4B. Regarding current trading prices, NVO is priced at $48.45, while JNJ trades at $246.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas JNJ's P/E ratio is 22.01. In terms of profitability, NVO's ROE is +0.61%, compared to JNJ's ROE of +0.34%. Regarding short-term risk, NVO is more volatile compared to JNJ. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check JNJ's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, ABBV has a market cap of 397.6B. Regarding current trading prices, NVO is priced at $48.45, while ABBV trades at $224.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas ABBV's P/E ratio is 95.32. In terms of profitability, NVO's ROE is +0.61%, compared to ABBV's ROE of -4.22%. Regarding short-term risk, NVO is less volatile compared to ABBV. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check ABBV's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, NVS has a market cap of 314.5B. Regarding current trading prices, NVO is priced at $48.45, while NVS trades at $163.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas NVS's P/E ratio is 22.78. In terms of profitability, NVO's ROE is +0.61%, compared to NVS's ROE of +0.33%. Regarding short-term risk, NVO is more volatile compared to NVS. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check NVS's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, MRK has a market cap of 305.4B. Regarding current trading prices, NVO is priced at $48.45, while MRK trades at $121.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas MRK's P/E ratio is 16.80. In terms of profitability, NVO's ROE is +0.61%, compared to MRK's ROE of +0.36%. Regarding short-term risk, NVO is less volatile compared to MRK. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check MRK's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, AMGN has a market cap of 202B. Regarding current trading prices, NVO is priced at $48.45, while AMGN trades at $375.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas AMGN's P/E ratio is 26.34. In terms of profitability, NVO's ROE is +0.61%, compared to AMGN's ROE of +0.97%. Regarding short-term risk, NVO is less volatile compared to AMGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check AMGN's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, GILD has a market cap of 187.8B. Regarding current trading prices, NVO is priced at $48.45, while GILD trades at $151.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas GILD's P/E ratio is 18.58. In terms of profitability, NVO's ROE is +0.61%, compared to GILD's ROE of +0.41%. Regarding short-term risk, NVO is less volatile compared to GILD. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check GILD's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, PFE has a market cap of 151.6B. Regarding current trading prices, NVO is priced at $48.45, while PFE trades at $26.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas PFE's P/E ratio is 19.60. In terms of profitability, NVO's ROE is +0.61%, compared to PFE's ROE of +0.09%. Regarding short-term risk, NVO is less volatile compared to PFE. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check PFE's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, BMY has a market cap of 123.6B. Regarding current trading prices, NVO is priced at $48.45, while BMY trades at $60.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas BMY's P/E ratio is 17.54. In terms of profitability, NVO's ROE is +0.61%, compared to BMY's ROE of +0.39%. Regarding short-term risk, NVO is less volatile compared to BMY. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check BMY's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, GSK has a market cap of 120.1B. Regarding current trading prices, NVO is priced at $48.45, while GSK trades at $60.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas GSK's P/E ratio is 15.75. In terms of profitability, NVO's ROE is +0.61%, compared to GSK's ROE of +0.30%. Regarding short-term risk, NVO is less volatile compared to GSK. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check GSK's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, SNY has a market cap of 113.6B. Regarding current trading prices, NVO is priced at $48.45, while SNY trades at $47.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas SNY's P/E ratio is 19.48. In terms of profitability, NVO's ROE is +0.61%, compared to SNY's ROE of +0.11%. Regarding short-term risk, NVO is less volatile compared to SNY. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SNY's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, BIIB has a market cap of 28.2B. Regarding current trading prices, NVO is priced at $48.45, while BIIB trades at $192.08.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas BIIB's P/E ratio is 21.85. In terms of profitability, NVO's ROE is +0.61%, compared to BIIB's ROE of +0.07%. Regarding short-term risk, NVO is less volatile compared to BIIB. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check BIIB's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVO is priced at $48.45, while HZNP trades at $116.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVO's ROE is +0.61%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to HZNP. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check HZNP's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, GRFS has a market cap of 8B. Regarding current trading prices, NVO is priced at $48.45, while GRFS trades at $9.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas GRFS's P/E ratio is 14.46. In terms of profitability, NVO's ROE is +0.61%, compared to GRFS's ROE of +0.07%. Regarding short-term risk, NVO is less volatile compared to GRFS. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check GRFS's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, OGN has a market cap of 2.1B. Regarding current trading prices, NVO is priced at $48.45, while OGN trades at $7.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas OGN's P/E ratio is 11.25. In terms of profitability, NVO's ROE is +0.61%, compared to OGN's ROE of +0.24%. Regarding short-term risk, NVO is less volatile compared to OGN. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check OGN's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, CELG-RI has a market cap of 163.3M. Regarding current trading prices, NVO is priced at $48.45, while CELG-RI trades at $0.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.61%, compared to CELG-RI's ROE of +0.39%. Regarding short-term risk, NVO is less volatile compared to CELG-RI. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CELG-RI's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, CTOR has a market cap of 102.4M. Regarding current trading prices, NVO is priced at $48.45, while CTOR trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas CTOR's P/E ratio is -3.74. In terms of profitability, NVO's ROE is +0.61%, compared to CTOR's ROE of -0.55%. Regarding short-term risk, NVO is less volatile compared to CTOR. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CTOR's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, SCLX has a market cap of 69.4M. Regarding current trading prices, NVO is priced at $48.45, while SCLX trades at $8.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas SCLX's P/E ratio is -0.20. In terms of profitability, NVO's ROE is +0.61%, compared to SCLX's ROE of +1.81%. Regarding short-term risk, NVO is less volatile compared to SCLX. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SCLX's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, MIRA has a market cap of 49.8M. Regarding current trading prices, NVO is priced at $48.45, while MIRA trades at $1.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas MIRA's P/E ratio is -0.74. In terms of profitability, NVO's ROE is +0.61%, compared to MIRA's ROE of -9.79%. Regarding short-term risk, NVO is less volatile compared to MIRA. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check MIRA's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, SRXH has a market cap of 4.3M. Regarding current trading prices, NVO is priced at $48.45, while SRXH trades at $0.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas SRXH's P/E ratio is -0.75. In terms of profitability, NVO's ROE is +0.61%, compared to SRXH's ROE of +4.36%. Regarding short-term risk, NVO is less volatile compared to SRXH. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check SRXH's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, SCLXW has a market cap of 1.4M. Regarding current trading prices, NVO is priced at $48.45, while SCLXW trades at $0.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.61%, compared to SCLXW's ROE of +1.81%. Regarding short-term risk, NVO is more volatile compared to SCLXW. This indicates potentially higher risk in terms of short-term price fluctuations for NVO.Check SCLXW's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVO is priced at $48.45, while BDSIW trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas BDSIW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.61%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVO is less volatile compared to BDSIW. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check BDSIW's competition here

NVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, NVO stands at 210.9B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVO is priced at $48.45, while CRXT trades at $0.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

NVO currently has a P/E ratio of 12.96, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVO's ROE is +0.61%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVO is less volatile compared to CRXT. This indicates potentially lower risk in terms of short-term price fluctuations for NVO.Check CRXT's competition here